Akciğer Karsinomu Tedavisi Sırasında Beyin Metastazı Gelişimini Etkileyen Faktörler

Abstract

INTRODUCTION: Brain metastases are frequently seen in lung carcinomas and increase mortality. The aim of this study is to evaluate the factors affecting brain metastases occurrence and to determine survival after brain metastases in patients with lung cancer. METHODS: The study included 72 patients who were diagnosed with lung carcinoma and had no brain metastasis at the time of diagnosis. RESULTS: The diagnosis of adenocarcinoma was 40.3%, while small cell lung carcinoma (SCLC) was 31.9% and squamous cell carcinoma was 26.4%. At the time of diagnosis 30.6% of patients were in stage IVB, 29.2% in stage IIIB and 18.1% in stage IIIA group. There were 5 (6.9%) patients in stage I and II. N2 involvement was found in 66.7% of the patients and N3 involvement was found in 23.6% of the patients. In the initial diagnosis, distant metastasis was not present in 63.9% of the patients. The time to brain metastasis development was 10.0 months. The survial of the patients was 2.0 months after the development of brain metastasis. Only 8,3% (n: 6) of the patients are still alive. All these alive patients were diagnosed as adenocarcinoma. DISCUSSION AND CONCLUSION: In our study, despite the adequate treatment responses in the primary tumor, brain metastasis developed in the patients within one year and caused loss of life in two months. Mediastinal lymph node involvement, local advanced and metastatic stage disease and adenocancer histology are effective factors in the development of brain metastasis in lung carcinoma.